WALTHAM, Mass., Nov. 08, 2018 (GLOBE NEWSWIRE) -- Proteon Therapeutics, Inc. (Nasdaq: PRTO), a company developing novel, first-in-class
therapeutics to address the medical needs of patients with kidney and vascular diseases, today announced that Company management
will present at the Stifel 2018 Healthcare Conference in New York, NY on Tuesday, November 13, 2018 at 5:00 p.m. ET.
A live audio webcast of the presentation can be accessed by visiting the Investor and Media section of the
Company’s website at www.proteontherapeutics.com. A replay of the webcast will be archived on the Proteon
website following the presentation.
About Proteon Therapeutics
Proteon Therapeutics is committed to improving the health of patients with kidney and vascular diseases through
the development of novel, first-in-class therapeutics. Proteon's lead product candidate, vonapanitase, is an investigational drug
intended to improve hemodialysis vascular access outcomes. Proteon has completed enrollment in PATENCY-2, a Phase 3 clinical trial
evaluating vonapanitase in patients with chronic kidney disease undergoing surgical creation of a radiocephalic arteriovenous
fistula for hemodialysis. Proteon is also evaluating vonapanitase in a Phase 1 clinical trial in patients with peripheral artery
disease. For more information, please visit www.proteontx.com.
Investor Contact
George Eldridge, Proteon Therapeutics, Senior Vice President and Chief Financial Officer
781-890-0102
geldridge@proteontherapeutics.com
Media Contact
Ann Stanesa, Ten Bridge Communications
617-230-0347
proteon@tenbridgecommunications.com
